Literature DB >> 15470487

Identification of natural killer cell receptor phenotypes associated with leukemia.

S Verheyden1, M Bernier, C Demanet.   

Abstract

Natural killer (NK) cells play a key role in defense against tumor cells that have the capacity to downregulate human leukocyte antigen (HLA) class I expression. It has been reported that leukemic cells can have downregulated expression of HLA class I molecules. The polymorphic nature of NK cell receptor (NKR) genes generates diverse repertoires in the human population, which display specificity in the innate immune response. In the present study, 11 KIR and two CD94/NKG2 receptors were genotyped by PCR-SSP in 96 leukemic patients and 148 healthy Caucasians. Here, we report a significant increased frequency of the more inhibitory AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients compared to the controls (31.1% in healthy controls vs 51.0% in leukemic patients, Pc=0.002), which is related to the high prevalence of the inhibitory KIR2DL2 in this population (Pc=0.007). Moreover, two specific KIR phenotypes AB1 and AB9, including all inhibitory KIRs, were significantly associated with leukemic patients. Our study suggests that an important percentage of leukemic patients express a KIR phenotype in favor of escape from NK cell immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470487     DOI: 10.1038/sj.leu.2403525

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  Amazonian Amerindians exhibit high variability of KIR profiles.

Authors:  Paloma Daguer Ewerton; Mauro de Meira Leite; Milena Magalhães; Leonardo Sena; Eduardo José Melo dos Santos
Journal:  Immunogenetics       Date:  2007-06-06       Impact factor: 2.846

Review 3.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

Review 4.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

5.  Inhibitory KIR2DL2 Gene: Risk for Deep Endometriosis in Euro-descendants.

Authors:  Maria Lucia Carnevale Marin; Verônica Coelho; Jeane Eliete Laguila Visentainer; Hugo Vicentin Alves; Karen Francine Köhler; Marici Rached Rached; Mauricio Simões Abrão; Jorge Kalil
Journal:  Reprod Sci       Date:  2020-07-14       Impact factor: 3.060

6.  The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia.

Authors:  Adam J de Smith; Kyle M Walsh; Martha B Ladner; Siming Zhang; Carmen Xiao; Franziska Cohen; Theodore B Moore; Anand P Chokkalingam; Catherine Metayer; Patricia A Buffler; Elizabeth A Trachtenberg; Joseph L Wiemels
Journal:  Blood       Date:  2014-02-11       Impact factor: 22.113

Review 7.  Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Authors:  Jennifer D Moy; Jessica M Moskovitz; Robert L Ferris
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

Review 8.  Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Authors:  Amanda K Purdy; Kerry S Campbell
Journal:  Cancer Biol Ther       Date:  2009-12-28       Impact factor: 4.742

9.  Killer cell immunoglobulin-like receptor gene cluster predisposes to susceptibility to B-cell acute lymphoblastic leukemia in Chinese children.

Authors:  Mingyan Jiang; Xia Guo; Lixing Yuan; Ju Gao; Li Huo; Qiang Li
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

10.  KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.

Authors:  Meixin Shen; Yeh-Ching Linn; Ee-Chee Ren
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.